This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ACHC vs. THC: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ACHC vs. THC: Which Stock Is the Better Value Option?
Acadia Healthcare Opens Mental Health Unit With Tower Health
by Zacks Equity Research
Acadia Healthcare (ACHC) unveils a facility to fortify its foothold in the mental health and behavioral healthcare market.
Here's Why You Should Steer Clear of MEDNAX (MD) at Present
by Zacks Equity Research
Pressure from the COVID-19 impact on global economy and lack of solvency make MEDNAX (MD) an unattractive bet.
Are Options Traders Betting on a Big Move in Tenet Healthcare (THC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Tenet Healthcare (THC) stock based on the movements in the options market lately.
Tenet Healthcare Plunges 55.7% YTD: Will the Stock Rebound?
by Zacks Equity Research
Even though Tenet Healthcare (THC) endures the COVID-19 impact on global economy, it holds prospects to revive its fortunes with the help of its endeavors and strong fundamentals.
ACHC or THC: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ACHC vs. THC: Which Stock Is the Better Value Option?
Here's Why You Should Steer Clear of HCA Healthcare Now
by Zacks Equity Research
Elevated expenses and muted revenues due to coronavirus pandemic make HCA Healthcare (HCA) an unattractive bet.
Community Health to Sell Unit for Streamlining Operations
by Zacks Equity Research
Community Health (CYH) is set to sell hospital units for debt-reduction and business rejig.
Court Ruling on Price Transparency Unsettles Hospital Stocks
by Sapna Bagaria
Stocks of most hospital companies take a hit after the federal court retains the rules pertaining to pricing transparency.
Here's Why You Should Add Ensign Group to Your Portfolio
by Zacks Equity Research
Strategic initiatives and a healthy balance sheet make Ensign Group (ENSG) an attractive pick for investors.
MEDNAX's (MD) Strategic Initiatives to Streamline Operations
by Zacks Equity Research
MEDNAX (MD) declares several transformational activities, which augur well for the long term.
Why Is Tenet (THC) Up 17% Since Last Earnings Report?
by Zacks Equity Research
Tenet (THC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Should You Hold on to Tenet Healthcare (THC) Stock?
by Zacks Equity Research
Despite the recent drag in Tenet Healthcare's (THC) business volumes, the same is expected to bounce back, given its solid fundamentals and the strategic initiatives taken.
Hospital Industry's Dull Near-Term Outllook Induced by Coronavirus
by Sapna Bagaria
Revenue loss and cost rise due to coronavirus outbreak put hospital companies in a tight spot.
MEDNAX Plunges More Than 42% YTD: Will the Stock Rebound?
by Zacks.com
Even though MEDNAX (MD) endures the COVID-19 impact on global economy, it holds prospects to revive its fortunes with the help of its initiatives and strong fundamentals.
Here's Why You Should Stay Away From HCA Healthcare Now
by Zacks.com
Depressed revenues and elevated expenses make HCA Healthcare (HCA) an unattractive bet.
Why Should You Hold onto Acadia Healthcare Stock?
by Sapna Bagaria
Despite the recent drag in Acadia Healthcare's (ACHC) business volumes, the same is expected to bounce back, given the defensive demand for its mental and behavioral health business.
Ensign Group's (ENSG) Q1 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
Ensign Group's (ENSG) first-quarter 2020 results reflect strong revenues courtesy of robust segmental performance, partly offset by high costs.
MEDNAX Divests American Anesthesiology to Avoid Cash Losses
by Zacks Equity Research
MEDNAX (MD) sells its American Anesthesiology to NAPA for portfolio rationalization and averting the negative COVID-19 impact.
MEDNAX's (MD) Earnings Miss Estimates in Q1, Tumble Y/Y
by Zacks Equity Research
MEDNAX's (MD) Q1 results reflect the coronavirus adversities that drained its revenues and volumes.
Tenet Healthcare (THC) Q1 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Tenet Healthcare's (THC) Q1 results reflect a strong operating performance and an income tax benefit, partly offset by the coronavirus outbreak.
Tenet Healthcare (THC) Q1 Earnings Beat Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of 433.33% and -2.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Tenet Healthcare (THC) Q1 Earnings Expected to Decline
by Zacks Equity Research
Tenet (THC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Community Health Repeals 2020 Outlook Amid Coronavirus Woes
by Zacks Equity Research
Community Health (CYH) withdraws its current-year guidance amid prevalent market volatility induced by the COVID-19 spread.
Universal Health Plunges 31.4% YTD: Will It Bounce Back?
by Zacks Equity Research
Even though Universal Health (UHS) suffers the COVID-19 impact on global economy, it holds potential to stage a comeback by virtue of its solid fundamentals.